Revvity Inc (RVTY) Stock Price, Quote & News

Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 663 6900

Website: www.revvity.com

Address:

77 4th Avenue, Waltham, United States

StockAutoPro Aug. 31 at 6:53 AM

$RVTY: Buy target $88.11 Sell target $94.62 Consider diversifying portfolio with undervalued stocks in the RVTY sector for potential long-term gains.

0 · Reply

YouOnlyLiveTwice Aug. 27 at 4:43 PM

$RVTY glad I sold this 🐷… Horrible management

0 · Reply

ChartElite Aug. 26 at 11:35 PM

$RVTY tumbled almost 9% after cutting its 2025 earnings outlook due to lower lab volumes under China’s new reimbursement rules.

0 · Reply

StockAutoPro Aug. 25 at 1:13 AM

$RVTY: Buy target $92.15 Sell target $98.86 Strong Q3 earnings report could indicate potential growth for leading cybersecurity firm in RVTY sector.

0 · Reply

StockAutoPro Aug. 24 at 5:46 PM

$RVTY: Buy target $92.15 Sell target $98.86 Consider investing in RVTY sector: promising growth in digital services despite recent market volatility.

0 · Reply

StockAutoPro Aug. 21 at 4:35 PM

$RVTY: Buy target $88.81 Sell target $95.35 Strong Q1 earnings report indicates promising future growth potential in this RVTY sector stock.

0 · Reply

BostonNorthern Aug. 20 at 2:36 PM

$RVTY Undervalued!

0 · Reply

YouOnlyLiveTwice Aug. 15 at 10:42 AM

$RVTY The company is medical device.. This is the problem people lost bec they copy and paste from their software w NO clue about the company

0 · Reply

StockAutoPro Aug. 14 at 5:44 PM

$RVTY: Buy target $87.7 Sell target $94.19 Expect volatility ahead in RVTY sector; high interest rates could impact real estate investment trusts.

0 · Reply

StockAutoPro Aug. 12 at 4:48 PM

$RVTY: Buy target $84.0 Sell target $90.3 No insight available

0 · Reply

Revvity to Present at Upcoming Investor Conferences

Aug 6, 2025, 8:00 AM EDT - 25 days ago

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Jul 28, 2025, 2:47 PM EDT - 4 weeks ago

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Jul 28, 2025, 1:40 PM EDT - 4 weeks ago

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Jul 28, 2025, 12:25 PM EDT - 4 weeks ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

LNG NKE

Jul 28, 2025, 11:59 AM EDT - 4 weeks ago

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 8:13 AM EDT - 4 weeks ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ATAI

Jul 28, 2025, 8:09 AM EDT - 4 weeks ago

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Jul 28, 2025, 7:39 AM EDT - 4 weeks ago

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Jul 28, 2025, 6:00 AM EDT - 4 weeks ago

Revvity Announces Financial Results for the Second Quarter of 2025

Jul 24, 2025, 4:05 PM EDT - 5 weeks ago

Revvity Board Declares Quarterly Dividend

Jul 7, 2025, 8:00 AM EDT - 7 weeks ago

Revvity to Hold Earnings Call on Monday, July 28, 2025

Jun 2, 2025, 8:00 AM EDT - 3 months ago

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

May 19, 2025, 8:00 AM EDT - 3 months ago

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 9, 2025, 10:35 AM EDT - 4 months ago

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

Apr 28, 2025, 11:49 AM EDT - 4 months ago

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 9:14 AM EDT - 4 months ago

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Apr 28, 2025, 7:32 AM EDT - 4 months ago

Revvity beats quarterly estimates on steady demand for medical equipment

Apr 28, 2025, 6:00 AM EDT - 4 months ago

Revvity Announces Financial Results for the First Quarter of 2025

Apr 23, 2025, 8:00 AM EDT - 4 months ago

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

Apr 22, 2025, 8:00 AM EDT - 4 months ago

Revvity Fuels the Future of Cancer Science with New Research Solutions

RSSS

Apr 3, 2025, 8:00 AM EDT - 5 months ago

Revvity to Hold Earnings Call on Monday, April 28, 2025

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Mar 20, 2025, 1:00 PM EDT - 5 months ago

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

Mar 11, 2025, 12:00 PM EDT - 6 months ago

PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry

Mar 3, 2025, 8:00 AM EST - 6 months ago

Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Feb 20, 2025, 12:30 PM EST - 6 months ago

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

Jan 31, 2025, 9:34 AM EST - 7 months ago

Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript

Jan 31, 2025, 7:32 AM EST - 7 months ago

Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending

Jan 31, 2025, 6:00 AM EST - 7 months ago

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

Jan 23, 2025, 8:00 AM EST - 7 months ago

Revvity Ignites Scientific Breakthroughs at SLAS2025

Jan 13, 2025, 8:00 AM EST - 8 months ago

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

Jan 12, 2025, 5:00 PM EST - 8 months ago

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

Jan 10, 2025, 8:00 AM EST - 8 months ago

Revvity Announces FDA Clearance for First Automated Free Testosterone Test

Dec 17, 2024, 8:00 AM EST - 9 months ago

Revvity to Present at J.P. Morgan Healthcare Conference

Dec 16, 2024, 12:27 AM EST - 9 months ago

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Dec 13, 2024, 1:57 PM EST - 9 months ago

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

DHR

Nov 20, 2024, 8:00 AM EST - 10 months ago

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

Nov 19, 2024, 8:00 AM EST - 10 months ago

Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells

Nov 19, 2024, 8:00 AM EST - 10 months ago

Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 8:00 AM EST - 10 months ago

Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation

Nov 5, 2024, 2:06 PM EST - 10 months ago

These Analysts Revise Their Forecasts On Revvity Following Q3 Results

Nov 4, 2024, 12:30 PM EST - 10 months ago

Revitty (RVTY) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:55 AM EST - 10 months ago

Revvity cuts 2024 revenue forecast amid biotech spending slowdown

Nov 4, 2024, 6:00 AM EST - 10 months ago

Revvity Announces Financial Results for the Third Quarter of 2024

Oct 22, 2024, 9:00 AM EDT - 11 months ago

Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories

Oct 22, 2024, 8:00 AM EDT - 11 months ago

Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report

Oct 7, 2024, 8:00 AM EDT - 11 months ago

Revvity To Hold Earnings Call on Monday, November 4, 2024

Oct 2, 2024, 8:00 AM EDT - 11 months ago

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene

StockAutoPro Aug. 31 at 6:53 AM

$RVTY: Buy target $88.11 Sell target $94.62 Consider diversifying portfolio with undervalued stocks in the RVTY sector for potential long-term gains.

0 · Reply

YouOnlyLiveTwice Aug. 27 at 4:43 PM

$RVTY glad I sold this 🐷… Horrible management

0 · Reply

ChartElite Aug. 26 at 11:35 PM

$RVTY tumbled almost 9% after cutting its 2025 earnings outlook due to lower lab volumes under China’s new reimbursement rules.

0 · Reply

StockAutoPro Aug. 25 at 1:13 AM

$RVTY: Buy target $92.15 Sell target $98.86 Strong Q3 earnings report could indicate potential growth for leading cybersecurity firm in RVTY sector.

0 · Reply

StockAutoPro Aug. 24 at 5:46 PM

$RVTY: Buy target $92.15 Sell target $98.86 Consider investing in RVTY sector: promising growth in digital services despite recent market volatility.

0 · Reply

StockAutoPro Aug. 21 at 4:35 PM

$RVTY: Buy target $88.81 Sell target $95.35 Strong Q1 earnings report indicates promising future growth potential in this RVTY sector stock.

0 · Reply

BostonNorthern Aug. 20 at 2:36 PM

$RVTY Undervalued!

0 · Reply

YouOnlyLiveTwice Aug. 15 at 10:42 AM

$RVTY The company is medical device.. This is the problem people lost bec they copy and paste from their software w NO clue about the company

0 · Reply

StockAutoPro Aug. 14 at 5:44 PM

$RVTY: Buy target $87.7 Sell target $94.19 Expect volatility ahead in RVTY sector; high interest rates could impact real estate investment trusts.

0 · Reply

StockAutoPro Aug. 12 at 4:48 PM

$RVTY: Buy target $84.0 Sell target $90.3 No insight available

0 · Reply

YouOnlyLiveTwice Aug. 8 at 2:58 PM

$RVTY No reason to have this when you can get BDX @ 11X EPS This is over valued should be high $60’s

0 · Reply

robertdollar Aug. 8 at 2:34 PM

$RVTY I am really upset for buying this a tad early.

1 · Reply

YouOnlyLiveTwice Aug. 6 at 4:41 PM

$RVTY Just took out a major 10 year support line.. Looks like $80 next then a significant drop lower

1 · Reply

YouOnlyLiveTwice Aug. 6 at 4:04 PM

$RVTY I went back and listened to the CC First of all you can’t understand the CEO. Seconds the CFO is screaming while he goes over the numbers Third I have lots of respects for doctors but they can’t run companies

0 · Reply

d_risk Aug. 5 at 11:02 PM

$RVTY - Revvity Inc. Common Stock - 10Q - Updated Risk Factors RVTY’s 10-Q highlights heightened risks from customer concentration, order timing sensitivity, global conflicts, tariffs, supply chain fragility, fierce tech competition, acquisition challenges, cyber threats, regulatory complexity, licensing risks, and volatile market conditions impacting revenue, costs, and stock volatility. #CustomerConcentration #MarketVolatility #Cybersecurity #TechCompetition #SupplyChain 🟢 Added 🟠 Removed https://d-risk.ai/RVTY/10-Q/2025-08-05

0 · Reply

YouOnlyLiveTwice Aug. 4 at 4:26 PM

$RVTY CEO Morningstar is saying your stock is undervalued by 80 points w a target of $162 What’s your plan for the shareholders ? Either to sell the company or go private to realize the full potential of the company value.

0 · Reply

YouOnlyLiveTwice Aug. 1 at 2:47 PM

$RVTY How can Morningstar have any credibility so this stock is undervalued by 80 points?

1 · Reply

YouOnlyLiveTwice Jul. 31 at 8:11 PM

$RVTY Balance sheets, Revenue . Earnings, Product Innovation… Nothing matters in the medical device space. It’s a hated industry that’s been in a downtrend since 2022… The ONLY you win is if the company stock you’re holding gets bought out.

0 · Reply

YouOnlyLiveTwice Jul. 31 at 12:55 PM

$RVTY Morningstar has a target price of $162… Either they have no clue or this is significantly undervalued .

0 · Reply

jnxz0rz Jul. 31 at 12:02 AM

$RVTY what the f?

2 · Reply

YouOnlyLiveTwice Jul. 30 at 5:57 PM

$RVTY If no recovery then I will take profits and get in at a lower price

0 · Reply

YouOnlyLiveTwice Jul. 30 at 5:55 PM

$RVTY This is the 3rd day lost ER so usually the next day you see a recovery ..today volume is v low which is a positive ..

0 · Reply

Market Cap	10.46B
Revenue (ttm)	2.76B
Net Income (ttm)	270.39M
EPS (ttm)	N/A
PE Ratio	18.25
Forward PE	18.31
Profit Margin	9.81%
Debt to Equity Ratio	0.43

Volume	786,100
Avg Vol	1,281,352
Day's Range	N/A - N/A
Shares Out	116.07M
Stochastic %K	35%
Beta	0.91
Analysts	Strong Sell
Price Target	$115.56